Notwithstanding safety concerns and
narrow therapeutic labeling, Roche Holding’s (RHHBY-$69.63)
rheumatoid arthritis treatment Actmera has still managed to show respectable
sequential growth: January – September 2013 sales grew 33% to 763 million Swiss
francs ($826.9 million), likely due to study results presented last year
showing Actemra was more effective than Humira as monotherapy in reducing
common disease-activity endpoints of RA (e.g. reduction in tenderness and
swollen joints) in those sufferers who couldn’t take methotrexate, the
standard-of-care in most newly-diagnosed patients.
Recent events suggest that estimated
peak annual sales of $1.1 billion in 2017 could prove conservative, too.
Editor David J Phillips does not hold a
financial interest in any stocks mentioned in this article. The 10Q Detective
has a Full Disclosure Policy.
No comments:
Post a Comment